Article Text

Download PDFPDF
The antiphospholipid syndrome and its ‘non-criteria’ manifestations
  1. Fady Georges Joseph1,
  2. Husni W Habboush2
    1. 1 Royal Gwent Hospital, Department of Neurology, Newport, UK
    2. 2 Spire Cardiff Hospital, Cardiff, UK
    1. Correspondence to Dr Fady Georges Joseph, Department of Neurology, Royal Gwent Hospital, Newport NP20 2UB, UK; fady.joseph{at}wales.nhs.uk, fadygjoseph{at}gmail.com

    Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The antiphospholipid syndrome is characterised by thrombotic and/or recurrent fetal loss/pregnancy morbidity associated with persistent antiphospholipid antibodies, namely lupus anticoagulant, anticardiolipin antibodies or anti-ß2 glycoprotein-1 antibodies. It is defined as primary when occurring without any underlying autoimmune disorder or secondary when associated with chronic inflammatory conditions, such as systemic lupus erythematosus, Sjögren’s syndrome and rheumatoid arthritis.

    Although persistent antiphospholipid antibodies are associated with many other clinical manifestations, these are not considered diagnostic for the antiphospholipid syndrome. The most commonly associated neurological disorders are stroke, transient ischaemic attacks and migraine, but also sometimes epilepsy, transverse myelitis, multiple sclerosis-like presentations, ocular symptoms, Guillain-Barré syndrome, cognitive impairment, dementia and very rarely chorea.

    Neurologists frequently see patients who test positive for antiphospholipid antibody or lupus anticoagulant. These might be only mildly elevated, present transiently or have no discernible clinical relationship, and we therefore often appropriately dismiss them. Indeed, up to 5% of the normal population test positive for these antibodies. However, when significantly elevated and clinically relevant, they …

    View Full Text

    Footnotes

    • Competing interests None declared.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles

    Other content recommended for you